You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Boehringer Ingelheim
Dow
McKinsey

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

TROKENDI XR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Trokendi Xr patents expire, and what generic alternatives are available?

Trokendi Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in eight countries.

The generic ingredient in TROKENDI XR is topiramate. There are twenty-six drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the topiramate profile page.

US ANDA Litigation and Generic Entry Outlook for Trokendi Xr

A generic version of TROKENDI XR was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.

  Start Trial

Drug patent expirations by year for TROKENDI XR
Drug Prices for TROKENDI XR

See drug prices for TROKENDI XR

Drug Sales Revenue Trends for TROKENDI XR

See drug sales revenues for TROKENDI XR

Recent Clinical Trials for TROKENDI XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Supernus Pharmaceuticals, Inc.Phase 2
University of Minnesota - Clinical and Translational Science InstitutePhase 2

See all TROKENDI XR clinical trials

Paragraph IV (Patent) Challenges for TROKENDI XR
Tradename Dosage Ingredient NDA Submissiondate
TROKENDI XR CAPSULE, EXTENDED RELEASE;ORAL topiramate 201635 2014-05-12
TROKENDI XR CAPSULE, EXTENDED RELEASE;ORAL topiramate 201635 2014-04-03

US Patents and Regulatory Information for TROKENDI XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB RX Yes No   Start Trial   Start Trial   Start Trial
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 BC RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Boehringer Ingelheim
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.